Breaking down the latest scientific discoveries in longevity medicine.
All Papers
72 papers
Peptide Medicine
Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure: STARS Phase 3 Trial
Clinical Gastroenterology and Hepatology · 2026 · Joly et al.
This phase 3 STARS trial evaluated apraglutide, a long-acting GLP-2 analog peptide, in patients with short bowel syndrome and intestinal failure. Once-weekly treatment significantly reduced dependence on intravenous nutrition and increased the number of patients achieving digestive autonomy. Alongside drugs like teduglutide, it demonstrates that peptide therapeutics with rigorous trial evidence continue to reach patients, a standard Aether Medicine applies when evaluating any peptide therapy.
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease
Nature Medicine · 2026 · Kaplan et al.
This phase 3 SYNCHRONIZE-MASLD trial tested survodutide, a dual glucagon and GLP-1 receptor peptide agonist, in adults with obesity and fatty liver disease. Treatment produced profound reductions in liver fat, with up to 83 percent of participants achieving resolution of hepatic steatosis alongside meaningful weight loss. The study shows how peptide engineering is now directly reversing organ-level metabolic disease, moving peptide medicine further into mainstream therapeutics.
Combinations of stepping intensity and daily step counts against all-cause and cardiovascular disease mortality
British Journal of Sports Medicine · 2026 · Wei L et al.
Using device-measured activity data from tens of thousands of participants, this study showed that walking pace matters as much as volume. Brisk walkers achieved mortality risk reductions at 5,000 to 7,000 daily steps comparable to what slower walkers needed 10,000 steps to attain. For busy patients, this reframes the goal: intensity is a lever you can pull even when total step count is modest.
Muscular Strength and Mortality in Women Aged 63 to 99 Years
JAMA Network Open · 2026 · LaMonte MJ et al.
In older women aged 63 to 99, objective strength measures including grip strength and chair stands were strongly associated with lower all-cause mortality, independent of daily activity levels measured by accelerometer. Strength remained protective across every age bracket studied. The findings support making muscle strength a tracked clinical vital sign in longevity care, since preserving it appears to directly support late-life survival.
Long-term resistance training with all-cause and cause-specific mortality: assessing dose-response and joint associations with aerobic physical activity
British Journal of Sports Medicine · 2026 · Zhang Y et al.
This prospective cohort study followed nearly 150,000 adults and found that just 30 to 60 minutes of weekly resistance training was associated with lower all-cause and cardiovascular mortality. Combining strength training with recommended aerobic activity produced additive benefits. The message for patients is simple: even one or two strength sessions per week measurably supports longevity, and strength work is a pillar of preventive medicine, not an optional extra for athletes.
Blood Proteomics of Menopause Map to Brain Aging and Dementia Risk
Nature Medicine · 2026 · Wood AM et al.
This large proteomic study mapped blood protein changes across the menopausal transition and connected them to brain aging and dementia risk. Specific protein pathways that shift during midlife hormonal changes correlated with structural brain changes and later cognitive decline. The findings suggest midlife is a measurable, actionable window for brain protection, and that blood-based biomarkers may one day help individualize prevention strategies long before symptoms begin.
Opportunity for Improved Menopausal Hormone Therapy Prescribing
JAMA · 2026 · Bartz D et al.
This JAMA perspective reviews menopausal hormone therapy prescribing in light of current evidence and regulatory updates. It argues that appropriately selected early-initiation therapy offers meaningful benefits for symptoms and bone, that modern routes such as transdermal estradiol carry lower clot risk than older oral formulations, and that outdated prescribing habits have left many appropriate candidates undertreated. It reflects a growing mainstream reappraisal of hormone therapy that clinicians are now translating into more individualized care.
Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness
Nature Aging · 2026 · Eskiocak et al.
Researchers used engineered CAR T cells to selectively remove senescent cells that accumulate in the aging intestine. These worn-out cells were shown to impair intestinal stem cell function and weaken the gut barrier. Clearing them restored tissue regeneration, reduced local inflammation, and improved organ function in aged models. The study demonstrates that targeted cellular therapies can address a root driver of tissue aging, though this remains preclinical research not yet available for patients.
A geroprotective probiotic and its functional metabolite counteract inflammaging to extend healthspan
Nature Aging · 2026 · Lu et al.
This research identified a probiotic strain, Bifidobacterium pseudocatenulatum, that consistently declines in humans with age, along with its functional metabolite. Supplementing with either the strain or the metabolite reduced multi-organ inflammatory signaling, restored gut barrier integrity, and improved cognitive and motor function in aged animal models. The study links specific microbiome changes to inflammaging and suggests microbiome-targeted strategies may eventually complement broader anti-inflammatory approaches. Human studies are still needed before specific strains can be recommended as therapy.
Therapeutic plasma exchange for MOG antibody-associated disease attacks: a systematic review and meta-analysis
Multiple Sclerosis and Related Disorders · 2026 · de Araujo et al.
This analysis pooled 49 clinical studies covering 475 flare episodes of MOG antibody disease, a neuro-inflammatory condition. Therapeutic plasma exchange achieved an overall clinical response rate of about 90 percent, with roughly 30 percent of patients reaching full neurological recovery. The evidence supports TPE as an effective tool for rapidly removing pathogenic antibodies during acute neuro-inflammatory attacks, consistent with its established role in antibody-mediated neurologic disease.
TNFR1 signaling connects inflammation to impaired fatty acid oxidation to drive intestinal stem cell aging
Nature Aging · 2026 · Wang et al.
This study established a direct mechanism connecting systemic inflammation to stem cell decline: circulating TNF alpha, a pro-inflammatory signal that rises with age, suppresses mitochondrial energy metabolism in intestinal stem cells through its receptor TNFR1. Blocking this signaling restored stem cell metabolism and regenerative capacity in animal models. The work strengthens the case that controlling chronic inflammation is not just about comfort, it is about preserving the body's capacity to repair its own tissues.
Plasma Exchange in Myeloma-Associated Acute Kidney Injury: A Multicenter Propensity-Matched Cohort Study
Journal of Clinical Apheresis · 2026 · O'Brien et al.
This large real-world study of over 5,000 patients examined whether adding plasma exchange to modern anti-myeloma therapy improves kidney recovery in patients with myeloma-associated acute kidney injury. Plasma exchange did not significantly reduce short- or long-term dialysis dependence or mortality. The findings are a useful reminder that plasma exchange has well-established indications, but its benefits do not automatically extend to every condition where antibodies or proteins circulate; evidence must be evaluated indication by indication.
Sex-specific trajectories of nonlinear immune aging at single-cell level
Nature Communications · 2026 · Park et al.
By analyzing nearly 3.8 million immune cells from 1,828 healthy people, researchers mapped how the human immune system ages at single-cell resolution. The study found the immune system does not decline gradually but shifts sharply around age 40 in helper T cells and after 60 in killer T cells, with distinct differences between women and men. These nonlinear transitions mark windows where proactive immune monitoring and intervention may matter most.
Inflammaging: Experimental Insights and Translational Advances
European Journal of Immunology · 2026 · Cossarizza A et al.
Modern longevity science is moving from understanding immune aging to actively reversing it. This state-of-the-art study details how novel clinical interventions can calm overactive inflammatory pathways and reboot immune cell function. Utilizing targeted therapies to restore immune balance helps protect the body against infections, chronic diseases, and systemic decline as we age.
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers
Pharmaceutics · 2026 · Mateescu DM et al.
BPC-157 is a therapeutic peptide derived from a protein naturally found in human gastric juice that plays a vital role in protecting and repairing tissues. Research shows that it promotes blood vessel growth, speeds up tendon and joint recovery, and helps heal the gut lining. Understanding these cellular repair mechanisms allows clinicians to leverage peptide therapies for faster recovery from injuries and improved gut health.
Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty
Cell Stem Cell · 2026 · Ruiz JG et al.
Aging frailty is characterized by chronic inflammation, loss of muscle stamina, and reduced stem cell activity throughout the body. In this rigorous phase 2b clinical trial, receiving intravenous stem cell therapy led to significant improvements in walking distance, physical endurance, and mental clarity in older adults. Stem cell therapy helps rebuild the body's regenerative capacity, reducing age-related frailty from the cellular level up.
Plasma-based strategies for systemic rejuvenation: critical perspectives on clinical translation
GeroScience · 2026 · Gulej R et al.
Therapeutic plasma exchange is rapidly emerging as one of the most exciting clinical tools in longevity medicine. This updated comprehensive review outlines the exact clinical standards, safety guidelines, and monitoring metrics used to perform plasma filtration procedures safely. By establishing rigorous clinical standards, plasma exchange can be seamlessly integrated into comprehensive anti-aging programs.
Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
Aging (Albany NY) · 2025 · Moel et al.
The PEARL trial evaluated intermittent low-dose rapamycin for 48 weeks in healthy older adults. Weekly dosing was well tolerated with a safety profile comparable to placebo, and participants showed improvements in lean tissue mass, particularly women. This is among the first randomized human trials supporting targeted mTOR modulation for healthy aging, an important proof of concept, though long-term outcome data are not yet available and rapamycin remains off-label for this purpose.
Multi-organ and multi-omics biological aging clocks digitize human aging
Nature Aging · 2025 · Wen et al.
This multi-cohort study built biological aging clocks for individual organs using multi-omics data from thousands of participants. Organ-specific age acceleration predicted future chronic disease, cognitive decline, and mortality independently of chronological age. The practical implication is significant: your heart, liver, kidneys, and brain can age at different rates, and knowing which organ is aging fastest allows interventions to be targeted where they matter most.
Physical activity as a modifiable risk factor in preclinical Alzheimer's disease
Nature Medicine · 2025 · Yau et al.
This longitudinal study combined objective physical activity monitoring with brain imaging and amyloid and tau biomarkers in older adults with preclinical Alzheimer pathology. Higher daily physical activity was associated with slower tau accumulation and reduced cognitive decline, even in people with elevated brain amyloid. The message is empowering: exercise actively modifies disease trajectory in the earliest, silent stage of neurodegeneration.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
New England Journal of Medicine · 2025 · Aronne et al.
This 72-week head-to-head phase 3 trial compared tirzepatide directly against semaglutide in adults with obesity or overweight without diabetes. Tirzepatide produced an average weight loss of 20.2 percent compared with 13.7 percent for semaglutide. The findings confirm that targeting both GIP and GLP-1 receptors yields greater metabolic benefit than GLP-1 activation alone. For patients and clinicians, the study helps individualize medication selection, since efficacy, tolerability, and cost all factor into choosing between these therapies.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
New England Journal of Medicine · 2025 · Garvey et al.
This phase 3 REDEFINE-1 trial tested a fixed-dose combination of cagrilintide, a long-acting amylin analog, with semaglutide in adults with obesity. The combination achieved average weight loss of 22.7 percent at 68 weeks, exceeding single-agent therapy. Amylin and GLP-1 are complementary gut hormones that regulate satiety through different pathways, and activating both is emerging as the next frontier in metabolic medicine.
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
New England Journal of Medicine · 2025 · Sanyal et al.
This phase 3 trial evaluated once-weekly semaglutide in patients with moderate to advanced fibrosis from metabolic dysfunction-associated steatohepatitis, the progressive form of fatty liver disease. Semaglutide resolved active liver inflammation without worsening fibrosis in 62.9 percent of patients and significantly improved fibrosis in 37.0 percent. The study marks a shift where incretin therapies address not just weight but the organ damage metabolic dysfunction leaves behind.
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
New England Journal of Medicine · 2025 · Ji et al.
This phase 3 GLORY-1 trial evaluated once-weekly mazdutide, a dual GLP-1 and glucagon receptor co-agonist peptide, in adults with overweight or obesity. Over 48 weeks, patients achieved dose-dependent weight reductions up to 14.0 percent, with improvements in blood pressure, lipids, and liver enzymes. The trial adds to growing evidence that rationally designed peptide co-agonists can deliver multi-system metabolic benefits, a design principle now moving through late-stage clinical development.
A blood-based epigenetic clock for intrinsic capacity predicts mortality and is associated with clinical, immunological and lifestyle factors
Nature Aging · 2025 · Fuentealba M et al.
Researchers developed DNAmIC, a blood-based epigenetic clock designed to measure intrinsic capacity, the combined physical and cognitive reserve that determines how well we age. Unlike clocks trained on chronological age alone, DNAmIC predicted mortality and functional decline across independent cohorts and responded to modifiable lifestyle factors. This kind of functional biomarker moves biological age testing closer to what patients actually care about: not a number, but resilience and capability over time.
Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial
Nature Aging · 2025 · Bischoff-Ferrari HA et al.
This analysis of the three-year DO-HEALTH randomized trial tested whether vitamin D, omega-3, and simple home exercise slow epigenetic biological aging in adults over 70. The combination of omega-3 and exercise significantly decelerated aging across multiple DNA methylation clocks, while individual interventions showed only modest trends. It is among the first randomized trial evidence that combined lifestyle interventions can measurably slow molecular aging markers, and it reinforces that modest, stackable habits can compound.
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
New England Journal of Medicine · 2025 · Nicholls SJ et al.
The BROADWAY phase 3 trial evaluated obicetrapib, a once-daily oral CETP inhibitor, in high-risk patients already on maximal statin therapy. The drug produced significant additional reductions in LDL cholesterol and apolipoprotein B, along with increases in HDL, with a safety profile comparable to placebo. It adds a promising oral option for patients who need more lipid lowering than standard therapy achieves. Whether these lipid changes translate into fewer heart attacks and strokes will be answered by the ongoing outcomes trial, which is the real test of clinical value.
Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial
JAMA Cardiology · 2025 · Rosenson RS et al.
This secondary analysis of the OCEAN(a)-DOSE trial examined how lowering Lp(a) with olpasiran affects oxidized phospholipids, highly atherogenic and pro-inflammatory particles carried on apolipoprotein B. Treatment reduced these particles in a dose-dependent manner without disrupting systemic immune function. The study illustrates how Lp(a) lowering may reduce not just cholesterol burden but the inflammatory vascular injury associated with it.
Tau PET Positivity in Individuals With and Without Cognitive Impairment
Nature Neuroscience · 2025 · Ossenkoppele R et al.
Using tau PET imaging across multiple cohorts, researchers mapped the transition from normal aging to early Alzheimer's pathology. The study found that tau accumulation in specific cortical regions marks a critical turning point toward clinical progression, even in people with no cognitive symptoms yet. Identifying this stage matters because it may define the window in which disease-modifying treatments are most useful. PET imaging also carries cost and access limitations that blood-based testing is beginning to address.
Plasma p-tau217 Identifies Cognitively Normal Older Adults Who Will Develop Cognitive Impairment in a 10-Year Window
Alzheimer's & Dementia · 2025 · Yakoub Y et al.
This 10-year prospective study tested whether a simple blood biomarker, plasma phosphorylated tau 217, could predict future cognitive decline in symptom-free older adults. Elevated baseline p-tau217 accurately identified people who went on to develop cognitive impairment over the following decade. The study strengthens the case that Alzheimer's disease can be detected through a blood test years before symptoms appear, creating a window for preventive lifestyle and medical interventions. Screening must still be paired with clinical evaluation, since biomarker positivity alone does not equal a diagnosis.
Menopause Hormone Therapy: 30 Years of Advances and Controversies
Journal of Clinical Endocrinology & Metabolism · 2025 · Sarvaideo J et al.
This state-of-the-art review synthesizes 30 years of hormone therapy evidence. Its central conclusion: outcomes depend heavily on the timing of initiation, patient age, and route of administration. Early initiation of transdermal estradiol with micronized progesterone shows favorable effects on metabolic health, bone density, and mortality in observational data. The review aligns clinical practice around the window of opportunity paradigm, while acknowledging that randomized long-term outcome data for modern regimens remain limited.
Association Between Menopause Age and Estradiol-Based Hormone Therapy With Cognitive Performance in Cognitively Normal Women in the CLSA
Neurology · 2025 · Puri TA et al.
Using data from over 10,000 cognitively normal women in the Canadian Longitudinal Study on Aging, this study linked earlier menopause to subtle cognitive deficits, and found that estradiol-based hormone therapy was associated with mitigation of that risk when started near menopause onset. Timing was the critical variable, echoing the broader theme that hormone therapy outcomes depend on when, not just whether, treatment is used. As with all observational nutrition, association does not prove causation, and individual decisions require clinical assessment.
Lepodisiran: A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
New England Journal of Medicine · 2025 · Nissen SE et al.
This phase 2 trial evaluated lepodisiran, an injectable small interfering RNA that silences the gene responsible for producing lipoprotein(a), a largely genetically determined cardiovascular risk factor. A single high dose reduced Lp(a) by more than 94 percent for up to 48 weeks, with good tolerability. If ongoing outcomes trials confirm benefit, infrequent gene-silencing injections could become a practical way to manage a risk factor that diet and exercise barely move.
Reversing lysosomal dysfunction restores youthful state in aged hematopoietic stem cells
Cell Stem Cell · 2025 · Arif et al.
This study showed that lysosomes, the recycling centers inside blood-forming stem cells, become hyperacidic and dysfunctional with age, triggering chronic inflammatory signaling inside the cells. Pharmacologically correcting this dysfunction restored the stem cells' structural integrity and increased their regenerative capacity more than eightfold in laboratory models. The work identifies cellular waste clearance as a reversible driver of stem cell aging, and a promising target for future regenerative therapies.
Organ-Specific Dedifferentiation and Epigenetic Remodeling in In Vivo Reprogramming
Aging Cell · 2025 · Jo et al.
This review evaluates partial epigenetic reprogramming, the transient expression of Yamanaka transcription factors that can return mature cells to a more youthful state without erasing their identity. The authors analyze how different organs respond and detail safety strategies such as cyclic induction and targeted delivery that reduce cancer risk. It provides a translational roadmap for a technology that remains experimental but is among the most closely watched frontiers in cellular medicine.
Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange
Aging Cell · 2025 · Fuentealba et al.
In a randomized placebo-controlled trial in adults over 50, researchers used epigenetic, proteomic, and metabolomic profiling to measure how therapeutic plasma exchange affects biological aging markers. Plasma exchange significantly reduced measured biological age across multiple epigenetic clocks compared with placebo, and a protocol combining plasma exchange with IV immunoglobulin produced the largest reductions in age-related immune markers and circulating inflammatory proteins. The trial also confirmed procedure safety. Important limitations remain: this is a small trial, findings are biomarker-based rather than clinical outcomes, and it does not establish that TPE extends lifespan or prevents disease.
Extracellular vesicles from antler blastema progenitor cells reverse bone loss and mitigate aging-related phenotypes
Nature Aging · 2025 · Hao Y et al.
Exosomes are tiny membrane bubbles released by stem cells that carry biological instructions, growth factors, and genetic signals to surrounding tissues. This study showed that specialized stem cell exosomes could effectively reverse age-related bone loss and systemic tissue aging in advanced models. Cell-free exosome therapies represent one of the safest and most targeted approaches to cellular rejuvenation available today.
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
JAMA Neurology · 2024 · Ashton NJ et al.
Detecting Alzheimer's pathology traditionally required invasive spinal taps or expensive brain scans. This 2024 study validated a revolutionary blood test measuring 'p-tau217' that detects silent neurodegenerative changes with up to 97% accuracy. This breakthrough allows doctors to assess brain health during routine checkups long before memory symptoms ever begin.
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
The Lancet · 2024 · Livingston G et al.
The global Lancet Commission on dementia revealed that up to 45% of cognitive decline cases can be prevented by addressing 14 specific lifestyle and health factors. Key protective steps include managing LDL cholesterol, protecting your hearing and vision, staying physically active, and maintaining metabolic health. Proactive lifestyle modifications remain one of your most powerful tools for lifelong cognitive vitality.
Testosterone Treatment and Fractures in Men with Hypogonadism
NEJM · 2024 · Snyder PJ et al.
Age-related testosterone loss is directly tied to muscle wasting and thinning bones. Clinical data from the TRAVERSE fracture study shows that testosterone replacement improves bone architecture and volumetric density in men with low hormone levels. Pairing hormone therapy with strength training provides a well-rounded strategy for skeletal longevity.
The Women's Health Initiative Randomized Trials and Clinical Practice: A Review
JAMA · 2024 · Manson JE et al.
A comprehensive 20-year review published in JAMA clarified longstanding misconceptions about Menopausal Hormone Therapy (MHT). When started under age 60 or within 10 years of menopause, MHT is safe and offers significant long-term protection—reducing bone fractures, lowering diabetes risk, and decreasing overall mortality. Custom hormone therapy can safely enhance quality of life and long-term health during menopause.
Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 RCT
Nature Medicine · 2024 · Farr JN et al.
Bone density naturally declines with age because senescent cells build up inside bone tissue, disrupting normal repair processes. This Phase 2 study demonstrated that periodic, short-term senolytic therapy lowered senescent cell burden and stimulated new bone formation. This approach offers a novel way to preserve bone strength and prevent age-related fractures.
Scientists have identified 12 key processes inside our cells—known as the "Hallmarks of Aging"—that cause our bodies to decline over time. Rather than viewing diseases like heart disease or memory loss as separate issues, this research shows that they all stem from these shared cellular drivers. By identifying these root mechanisms, modern longevity medicine can target the primary causes of aging to keep you healthier and more vibrant for longer.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
NEJM · 2023 · Lincoff AM et al.
GLP-1 medications do far more than just assist with weight management; they directly shield your cardiovascular system. This major international study showed that semaglutide reduced the risk of heart attacks, strokes, and cardiovascular death by 20% in people without diabetes. These findings highlight how optimizing metabolic health directly protects your heart as you age.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
NEJM · 2023 · Jastreboff AM et al.
Scientists have developed a single compound called retatrutide that targets three distinct metabolic hormone receptors at once. In clinical trials, this triple-action therapy helped patients achieve unprecedented weight loss—up to 24% of total body weight—while clearing fatty liver deposits. This multi-pathway approach targets metabolic decline at its source.
For decades, slowing the progression of memory decline was a major challenge in medicine. This landmark trial showed that lecanemab, a therapy designed to clear toxic amyloid protein buildup from the brain, slowed cognitive decline by 27% in early-stage patients over 18 months. These results prove that catching and treating brain changes early can help preserve cognitive independence.
Donanemab in Early Symptomatic Alzheimer Disease: TRAILBLAZER-ALZ 2
JAMA · 2023 · Sims JR et al.
Donanemab is an advanced antibody designed to eliminate plaque buildup in brain tissue. Results from the TRAILBLAZER-ALZ 2 trial revealed that patients treated at earlier stages of brain aging experienced a 35% slowing in cognitive decline. In fact, nearly half of the treated patients showed no disease progression at all during the first year of treatment.
Cardiovascular Safety of Testosterone-Replacement Therapy
NEJM · 2023 · Lincoff AM et al.
For years, questions lingered regarding whether testosterone therapy affected heart health in aging men. The landmark TRAVERSE trial followed over 5,000 men and proved that properly prescribed testosterone replacement does not increase the risk of heart attacks or strokes. This research confirms that hormone optimization can be safely managed to support energy, muscle strength, and metabolic vitality.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
NEJM · 2023 · Nissen SE et al.
Many patients struggle to take statin medications due to muscle aches or weakness. The CLEAR Outcomes trial evaluated bempedoic acid, an oral medication that selectively targets cholesterol synthesis in the liver without affecting muscle tissue. The drug lowered LDL cholesterol by over 20%, reduced blood vessel inflammation, and cut major heart events by 13%.
Tirzepatide Once Weekly for the Treatment of Obesity
NEJM · 2022 · Jastreboff AM et al.
Excess weight and metabolic imbalance are major drivers of premature aging and chronic disease. In this landmark study, a once-weekly dual-hormone medication called tirzepatide helped adults lose over 20% of their total body weight on average. In addition to dramatic weight reduction, patients experienced significant improvements in blood sugar, cholesterol, and blood pressure levels.
Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction
JAMA Cardiology · 2022 · Marston NA et al.
Standard cholesterol panels measure the weight of cholesterol carried in your blood, but it is actually the number of lipid-carrying particles (measured by ApoB) that penetrate artery walls to cause blockages. This major study in JAMA Cardiology proved that ApoB is a superior predictor of heart attack risk compared to traditional LDL cholesterol. Tracking ApoB gives us a clearer picture for preventing arterial plaque buildup.
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
NEJM · 2022 · O'Donoghue ML et al.
Lipoprotein(a), or Lp(a), is a genetically inherited variant of cholesterol affecting 1 in 5 people that cannot be controlled through diet, exercise, or standard statins. This study published in NEJM evaluated olpasiran, a gene-silencing RNA therapy that reduced toxic Lp(a) levels by more than 95%. This therapeutic advance targets inherited cardiovascular risks that were once untreatable.
Muscle-strengthening activities and risk of major non-communicable diseases: systematic review and meta-analysis
British Journal of Sports Medicine · 2022 · Momma H et al.
While cardio exercises get a lot of attention, lifting weights and building strength are equally critical for long-term survival and health. This comprehensive study showed that engaging in just 30 to 60 minutes of strength training each week reduces overall risk of death and chronic disease by up to 17%. When resistance training is combined with aerobic exercise, overall mortality risk drops by an astounding 40%.
Cardiorespiratory Fitness and Mortality Risk Across the Spectra of Age, Race, and Sex
J Am Coll Cardiol · 2022 · Kokkinos P et al.
Regardless of your age, gender, or starting fitness level, boosting your cardiovascular endurance delivers dramatic survival advantages. Analyzing three-quarters of a million people, scientists found that moving out of the lowest fitness category reduced death risk by roughly half. This confirms that starting a personalized, progressive exercise routine at any point in life pays immediate and lasting health dividends.
Old plasma dilution reduces human biological age: a clinical study
GeroScience · 2022 · Kim D et al.
As we age, our blood plasma accumulates inflammatory proteins, cellular debris, and circulating factors that accelerate organ decline. This human clinical study showed that therapeutic plasma exchange—a process that filters out old plasma and replaces it with pure albumin—effectively resets key biological age clocks and reduces systemic inflammation. Diluting old plasma creates a younger, cleaner internal environment that supports organ health and cellular rejuvenation.
An aged immune system drives senescence and ageing of solid organs
Cell · 2021 · Yousefzadeh MJ et al.
Scientists long wondered whether organs age independently or if one master system triggers body-wide decline. This study published in Cell proved that an aging, dysfunctional immune system actively drives premature aging in other solid organs like the heart, liver, and kidneys. Maintaining a resilient, youthful immune system protects every organ in your body from accelerated wear and tear.
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Science · 2021 · Yoshino M et al.
NAD+ is a critical molecule that fuels energy production in every cell, but its levels drop dramatically as we age. This rigorous human study found that daily supplementation with NMN, an NAD+ building block, significantly improved muscle insulin sensitivity in prediabetic women. By restoring cellular energy pathways, NAD+ boosting helps your muscles efficiently absorb glucose and stay metabolically youthful.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
NEJM · 2021 · Wilding JPH et al.
Carrying extra visceral fat around vital organs drives systemic inflammation and accelerates aging. The STEP 1 trial demonstrated that weekly semaglutide enabled participants to lose nearly 15% of their body weight while significantly narrowing waist circumference. Furthermore, key markers of internal inflammation and blood sugar control improved across the board.
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Nature Communications · 2021 · Reynolds JC et al.
Mitochondria are best known as the cellular powerhouses that produce energy, but researchers have discovered they also release special messenger peptides like MOTS-c. This study showed that MOTS-c mimics the metabolic and physical performance benefits of intense physical exercise, preserving muscle strength and metabolic health as we age. For patients looking to maintain vitality, mitochondrial peptide therapies represent an exciting frontier in cellular energy restoration and healthy aging.
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: AMBAR Study
Alzheimer's & Dementia · 2020 · Boada M et al.
The AMBAR study was a major clinical trial examining whether clearing toxic proteins from the bloodstream could slow down brain aging and memory loss. The results demonstrated that regular therapeutic plasma exchange slowed the progression of cognitive decline in Alzheimer's patients by up to 61%. This proves that removing harmful factors from circulation protects brain cells and preserves cognitive function as we age.
Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin
Aging · 2020 · Mehdipour M et al.
For years, scientists debated whether young blood contained special rejuvenation factors or if old blood simply accumulated toxic signals that suppress healing. This groundbreaking research proved that simply removing old, inhibitory plasma and replacing it with a neutral saline-albumin solution triggered widespread tissue repair across the brain, liver, and muscle. Clearing out circulating cellular debris allows your body's native stem cells to repair tissue properly.
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
EBioMedicine · 2019 · Justice JN et al.
As we age, certain cells stop dividing but refuse to die, lingering in our tissues and releasing harmful inflammatory signals—earning them the nickname 'zombie cells.' This landmark clinical trial demonstrated that a short course of targeted natural and pharmaceutical compounds can selectively remove these cells in humans. Patients receiving the treatment experienced noticeable gains in mobility and physical performance, opening new doors for anti-aging therapies.
Reversal of epigenetic aging and immunosenescent trends in humans
Aging Cell · 2019 · Fahy GM et al.
Can we actually turn back our cellular clock? The pioneering TRIIM clinical study demonstrated that a targeted 1-year protocol combining growth hormone, DHEA, and metformin regenerated thymic tissue and reversed participants' biological age by an average of 1.5 years on DNA methylation tests. This research highlights how combined endocrine and metabolic strategies can slow or reverse biological aging.
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
The Lancet HIV · 2019 · Stanley TL et al.
Deep visceral fat stored around abdominal organs and inside the liver is one of the most dangerous drivers of chronic disease and accelerated aging. This landmark trial showed that targeted growth hormone secretagogue therapy significantly decreased liver fat accumulation and prevented liver scarring. For longevity patients, reducing visceral fat through peptide therapy is a powerful way to enhance metabolic health, protect liver function, and reduce long-term cardiovascular risk.
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease
EBioMedicine · 2019 · Hickson LJ et al.
As we age, some of our cells stop dividing but refuse to die, lingering as harmful "zombie cells" that secrete inflammatory toxins into surrounding tissues. This historic human trial proved that a targeted senolytic therapy could safely and selectively target and clear these senescent cells from human body tissue. Removing these damaged cells reduces systemic inflammation and allows healthy tissue regeneration.
Reversal of epigenetic aging and immunosenescent trends in humans
Aging Cell · 2019 · Fahy GM et al.
As we age, our thymus gland—which produces disease-fighting T-cells—gradually shrinks and turns to fat, causing our immune system to weaken. In the historic TRIIM study, researchers used a combination therapy to successfully regrow functional thymic tissue, reverse immune system decline, and turn back human epigenetic age clocks by an average of 2.5 years. Restoring youthful immune defense is a major key to preventing disease and extending healthy lifespan.
Inflammaging: a new immune-metabolic viewpoint for age-related diseases
Nature Reviews Endocrinology · 2018 · Franceschi C et al.
"Inflammaging" refers to the constant, low-grade internal inflammation that quietly develops as we get older, damaging healthy tissue and accelerating disease. This paper explains how factors like gut health, cellular stress, and immune fatigue trigger chronic inflammatory signals that fuel heart disease, diabetes, and memory loss. Identifying and resolving hidden sources of systemic inflammation is crucial for preserving lifelong health and vitality.
TORC1 inhibition enhances immune function and reduces infections in the elderly
Science Translational Medicine · 2018 · Mannick JB et al.
Our immune system naturally weakens as we age, making us more vulnerable to seasonal infections and viruses. This clinical trial showed that low doses of a targeted compound that moderates the 'mTOR' cellular pathway could safely reboot immune function in older adults. Participants had significantly fewer infections over the following year and responded much better to vaccines, proving that age-related immune decline can be slowed or reversed.
Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing
JAMA Network Open · 2018 · Mandsager K et al.
How well your heart and lungs deliver oxygen to your body during exercise—known as cardiorespiratory fitness or VO2 max—is one of the single best predictors of how long you will live. Studying over 120,000 individuals, researchers found that higher fitness levels drastically cut mortality risk, with no upper limit where exercise stopped being beneficial. Achieving elite aerobic fitness offers greater protection against premature death than quitting smoking or managing blood pressure.
Low-density lipoproteins cause atherosclerotic cardiovascular disease
European Heart Journal · 2017 · Ference BA et al.
Cardiovascular disease develops silently over decades as atherogenic particles accumulate inside artery walls. This landmark European consensus panel proved that atherogenic lipoproteins directly cause heart disease, and that total damage depends on cumulative lifelong exposure—much like 'pack-years' of smoking. Lowering your ApoB particle burden early in life protects your arteries and supports long-term cardiovascular health.
Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign
Circulation · 2016 · Ross R et al.
Leading medical authorities now recognize cardiorespiratory fitness (VO2 max) as a vital sign just as critical as blood pressure or heart rate. Measuring how efficiently your body utilizes oxygen provides unmatched insight into your overall health, organ reserve, and cellular aging rate. Tracking and optimizing this metric allows individuals to take active, measurable control of their healthspan.
As we get older, our natural production of growth hormone gradually declines, contributing to loss of muscle mass, decreased energy, and slower recovery. This clinical study evaluated CJC-1295, a long-acting peptide that prompts the body's pituitary gland to naturally release its own growth hormone in a safe, balanced manner. By stimulating natural production rather than replacing it artificially, growth hormone secretagogues help restore youthful metabolic repair, lean body mass, and recovery.
We review emerging research and translate complex science into practical clinical insights you can actually use.
Put The Science To Work
Ready To Apply This Research To Your Own Health?
Dr. Christian translates emerging longevity science into personalized, physician-led care. Schedule a consultation to discuss what the evidence means for you.